No Data
Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 53.45 Yuan From 51.31 Yuan, Keeps at Neutral
Hengrui Medicine 2024 Profit Up 47%, Revenue Rises 23%
Jiangsu Hengrui Pharmaceuticals (600276.SH): Sulfate of Amcasertib Tablets have obtained a pharmaceutical registration certificate.
Gelonghui, March 31st | Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company received the "Pharmaceutical Registration Certificate" approved by the National Medical Products Administration, approving the company's self-developed Class 1 Innovative Drug, SHR0302 Tablets, for a new indication to treat adult patients with moderate to severe active rheumatoid arthritis who have had inadequate responses or are intolerant to one or more TNF inhibitors. SHR0302 Tablets are a highly selective JAK1 inhibitor that exerts anti-inflammatory and immune-suppressing biological effects by inhibiting JAK1 signaling.
Hengrui Pharmaceutical: Summary of Hengrui Pharmaceutical\'s 2024 Annual Report
Hengrui Pharmaceutical: Hengrui Pharmaceutical 2024 Annual Report
Summary of Hengrui Pharmaceutical\'s 2024 Annual Report
Shareholders in Jiangsu Hengrui Medicine (SHSE:600276) Are in the Red If They Invested Three Years Ago
